Mediwhale Raises $12 Million in Series A2
Mediwhale, a Seoul, South Korea-based AI-powered health diagnostics company, has raised $12 million in Series A2 funding.
The round was led by Korea Development Bank (KDB), with contributions from Woori Venture Partners, IMM Investment, and Mirae Asset Securities.
Korea Development Bank is South Korea's state-owned development bank, founded in 1954 to help develop Korean industries and the country's economy. The bank's products and services include corporate loans, equity investments, public and corporate bonds, and debt and payment guarantees. KDB operates in 19 countries, including New York, London, Singapore, and Beijing.
With the funding, Mediwhale plans to enhance its AI algorithms, pursue U.S. FDA approval for Reti-CVD, and expand its global presence.
Founded in 2016, Mediwhale is an AI-powered health diagnostics company that aims to revolutionize early cardiovascular disease detection through its flagship product, Reti-CVD. It uses non-invasive retina scans to help prevent heart and kidney diseases. Mediwhale's solution employs deep learning algorithms to detect future disease risks even before symptoms appear. With over 7,200 cases utilized across 57 medical institutions in Korea, Mediwhale is dedicated to making preventative care more affordable, accessible, safe, and convenient.
Funding Details
Company: Mediwhale, Inc.
Raised: $12.0M
Round: Series A2
Funding Date: September 2024
Lead Investor: Korea Development Bank (KDB)
Additional Investors: Woori Venture Partners, IMM Investment, Mirae Asset Securities
Company Website: https://mediwhale.com/
Software Category: Health Diagnostics